Keybanc analyst Michael Turits downgrades Fortinet (NASDAQ:FTNT) from Overweight to Sector Weight.
Pfizer Announces Top-Line Results From Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine In Infants; Says 20vPnC Demonstrated Favorable Safety And Tolerability Profile
Pivotal top-line data demonstrate a four-dose series of 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in